ASH 2020 Meeting Highlights in Myelodysplastic Syndromes

ASH 2020 Meeting Highlights in Myelodysplastic Syndromes
ASH 2020 Meeting Highlights in Myelodysplastic Syndromes
CME, CPE, CNE
Mikkael A. Sekeres, MD; Guillermo Garcia-Manero, MD; Rami S. Komrokji, MD
Release Date: April 15, 2021
Expiration Date: April 15, 2022

In this activity, experts will discuss exciting abstracts from the 2020 ASH Annual Meeting related to myelodysplastic syndromes (MDS). Topics will include genomic and somatic mutations of MDS, personalized decision tools for MDS diagnosis, data on lenalidomide for non-transfusion-dependent, lower-risk del(5q) MDS, biomarkers that correlate with luspatercept response, the effect of luspatercept on MDS with ring sideroblasts, phase 2 trial result of imetelstat in lower-risk MDS, and therapeutic doublets such as azacitidine plus venetoclax and azacitidine plus pevonedistat in higher-risk MDS.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc.

Begin, Earn CreditView Only, No CreditGet Certificate